Intra-Cellular Therapies Income Statement

Financials in millions SGD. Fiscal year is January - December.

Millions SGD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	11.19	10.85	11.1	11.7	11.19
Other Revenue	0.21	0.21	0.08	0.09	0.12
Revenue	11.4	11.06	11.17	11.79	11.32
Revenue Growth (YoY)	3.00%	-0.95%	-5.23%	4.16%	-
Cost of Revenue	6.98	6.58	6.17	6.58	6.36
Gross Profit	4.42	4.48	5	5.2	4.95
Selling, General & Admin	0.14	0.09	0.09	0.11	0.12
Other Operating Expenses	0.78	0.53	0.31	0.46	0.59
Operating Expenses	1.94	1.36	1.19	1.45	1.57
Operating Income	2.48	3.12	3.81	3.75	3.39
Interest Expense	-0.07	-0.08	-0.08	-0.06	-0.02
Currency Exchange Gain (Loss)	0.05	-0.03	-0.07	-0.01	-0.02
Other Non Operating Income (Expenses)	0.03	-	-	0.17	0.15
EBT Excluding Unusual Items	2.49	3.02	3.66	3.85	3.5
Gain (Loss) on Sale of Assets	-	-	-0	-	-
Other Unusual Items	-	-0.79	-0.38	0.33	0.33
Pretax Income	2.49	2.23	3.28	4.18	3.84
Income Tax Expense	0.41	0.49	0.41	0.7	0.73
Earnings From Continuing Operations	2.08	1.74	2.88	3.48	3.11
Minority Interest in Earnings	-	-0.06	-0.11	-0.15	-0.11
Net Income	2.08	1.69	2.76	3.34	3
Net Income to Common	2.08	1.69	2.76	3.34	3
Net Income Growth	23.31%	-38.98%	-17.25%	11.34%	-
Shares Outstanding (Basic)	130	130	130	130	130
Shares Outstanding (Diluted)	130	130	130	130	130
EPS (Basic)	0.02	0.01	0.02	0.03	0.02
EPS (Diluted)	0.02	0.01	0.02	0.03	0.02
EPS Growth	23.31%	-38.98%	-17.25%	11.34%	-
Free Cash Flow	1.75	1.89	3.29	4.01	4.58
Free Cash Flow Per Share	0.01	0.01	0.03	0.03	0.04
Dividend Per Share	0.010	0.010	-	-	-
Gross Margin	38.79%	40.49%	44.74%	44.14%	43.78%
Operating Margin	21.78%	28.19%	34.11%	31.83%	29.92%
Profit Margin	18.24%	15.24%	24.74%	28.33%	26.51%
Free Cash Flow Margin	15.38%	17.11%	29.48%	34.05%	40.51%
EBITDA	2.9	3.43	4.23	4.21	3.88
EBITDA Margin	25.40%	30.96%	37.86%	35.75%	34.26%
D&A For EBITDA	0.41	0.31	0.42	0.46	0.49
EBIT	2.48	3.12	3.81	3.75	3.39
EBIT Margin	21.78%	28.19%	34.11%	31.83%	29.92%
Effective Tax Rate	16.37%	21.89%	12.37%	16.67%	18.91%

Updated Aug 9, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.